 

my chemicalbook

ChemicalBook Product Catalog Biochemical Engineering Nucleoside drugs Nucleotides and their analogs 5-Fluorouracil

1/2

5-Fluorouracil NEW

$0.10 1000KG

$5.00 1KG

Min. Order1KG
Purity98%
Cas No51-21-8
Supply Abilityg-kg-tons, free sample is available
Update time2024-04-09

Henan Fengda Chemical Co., Ltd

1YR

China

Since2023-02-10

AddressRoom 01, 2288 E05, Building 14, East Henan University, Science and Technology Park, 279 Xisanhuan Ro

show less show more

Chemical Properties

Product Name	5-Fluorouracil
CAS No	51-21-8
EC-No
Min. Order	1KG
Purity	98%
Supply Ability	g-kg-tons, free sample is available
Release date	2024/04/09

1. Materials information

Names

Name	5-fluorouracil
Synonym	More Synonyms

Fluorouracil Biological Activity

Description	5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase thus depleting intracellular dTTP pools.
Related Catalog	Signaling Pathways >> Cell Cycle/DNA Damage >> Nucleoside Antimetabolite/Analog Research Areas >> Cancer
In Vitro	5-Fluorouracil (5-Fu) and doxorubicin (Dox) show synergistic anticancer efficacy. The IC50 value of 5-Fu/Dox-DNM toward human breast cancer (MDA-MB-231) cells is 0.25 μg/mL, presenting an 11.2-fold and 6.1-fold increase in cytotoxicity compared to Dox-DNM and 5-Fu-DNM, respectively[1]. In 5-fluorouracil (5-FU) and CDDP treated NFBD1-inhibited NPC cells, the NFBD1 expression in NPC CNE1 cell lines is depleted using lentivirus-mediated short hairpin RNA, and the sensitivity of these cells is elevated. NFBD1 knockdown leads to an obvious induction of apoptosis in CDDP- or 5-FU-treated CNE1 cells[3].
In Vivo	5-Fluorouracil (23 mg/kg, 3 times/week) for 14 days, induces accelerated gastrointestinal transit associated with acute intestinal inflammation at day 3 after the start of treatment, which may have led to persistent changes in the ENS observed after days 7 and 14 of treatment contributing to delayed gastrointestinal transit and colonic dysmotility[2].
Animal Admin	Mice receive intraperitoneal injections of 5-FU (23 mg/kg), 3 times a week via a 26 gauge needle. 5-FU is dissolved in 100% dimethyl sulfoxide (DMSO) to make 1 M/L stock solution refrigerated at −20°C. The stock is then defrosted and diluted with sterile water to make 0.1 M/L (10% DMSO) solutions for intraperitoneal injections. The dose of 5-FU is calculated to be equivalent to standard human dose per body surface area. The low doses of 5-FU (10-40 mg/kg) have been shown to have antitumor efficacy in mouse models of cancer. Sham-treated mice received 10% DMSO in sterile water via intraperitoneal injection three times a week via a 26 gauge needle. The injected volumes are calculated to the body weight; the maximum volume does not exceed 200 μL per injection. Mice are euthanized via cervical dislocation at 3 (2 treatments), 7 (3 treatments), and 14 (6 treatments) days after the first injection and colon is collected for in vitro experiments.
References	[1]. Han R, et al. Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy. J Drug Target. 2016 Jun 29:1-28. [Epub ahead of print] [2]. McQuade RM, et al. Gastrointestinal dysfunction and enteric neurotoxicity following treatment with anticancer chemotherapeutic agent 5-fluorouracil. Neurogastroenterol Motil. 2016 Jun 28. [3]. Zeng Q, et al. Knockdown of NFBD1/MDC1 enhances chemosensitivity to cisplatin or 5-fluorouracil in nasopharyngeal carcinoma CNE1 cells. Mol Cell Biochem. 2016 Jul;418(1-2):137-46. [4]. Yin L, et al. Antitumor effects of oncolytic herpes simplex virus type 2 against colorectal cancer in vitro and in vivo. Ther Clin Risk Manag. 2017 Feb 7;13:117-130.

Chemical & Physical Properties

Density	1.7±0.1 g/cm3
Boiling Point	401.4±48.0 °C at 760 mmHg
Melting Point	282-286 °C (dec.)(lit.)
Molecular Formula	C4H3FN2O2
Molecular Weight	130.077
Flash Point	196.5±29.6 °C
Exact Mass	130.017853
PSA	65.72000
LogP	-2.10
Vapour Pressure	0.0±1.0 mmHg at 25°C
Index of Refraction	1.596
Storage condition	Store at 0-5
Stability	Stable. Light sensitive. Combustible. Incompatible with strong oxidizing agents, strong bases.
Water Solubility	12.2 g/L 20 ºC

MSDS

Fluorouracil MSDS(Chinese)

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
YR0350000

CHEMICAL NAME :
Uracil, 5-fluoro-

CAS REGISTRY NUMBER :
51-21-8

LAST UPDATED :
199710

DATA ITEMS CITED :
156

MOLECULAR FORMULA :
C4-H3-F-N2-O2

MOLECULAR WEIGHT :
130.09

WISWESSER LINE NOTATION :
T6MVMVJ EF

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
Standard Draize test

ROUTE OF EXPOSURE :
Administration onto the skin

SPECIES OBSERVED :
Human

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Human

DOSE/DURATION :
450 mg/kg/30D

TOXIC EFFECTS :
Gastrointestinal - other changes Blood - changes in bone marrow (not otherwise specified) Tumorigenic - active as anti-cancer agent

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human

DOSE/DURATION :
6 mg/kg/3D

TOXIC EFFECTS :
Cardiac - EKG changes not diagnostic of specified effects Cardiac - other changes Lungs, Thorax, or Respiration - other changes

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
150 mg/kg/17W-I

TOXIC EFFECTS :
Blood - other hemolysis with or without anemia

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human - man

DOSE/DURATION :
39 mg/kg/1D-I

TOXIC EFFECTS :
Cardiac - changes in coronary arteries

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Human - woman

DOSE/DURATION :
27 mg/kg/4D-C

TOXIC EFFECTS :
Cardiac - other changes

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
230 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
70 mg/kg

TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
217 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
245 mg/kg

TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - nausea or vomiting

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intramuscular

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
240 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Parenteral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
500 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Rectal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
884 mg/kg

TOXIC EFFECTS :
Gastrointestinal - hypermotility, diarrhea Gastrointestinal - other changes

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
115 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
100 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
169 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
81 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intracerebral

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
41600 ug/kg

TOXIC EFFECTS :
Peripheral Nerve and Sensation - sensory change involving peripheral nerve Sense Organs and Special Senses (Eye) - ptosis Sense Organs and Special Senses (Eye) - effect, not otherwise specified

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Intratracheal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
200 mg/kg

TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Unreported

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
171 mg/kg

TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
30 mg/kg

TOXIC EFFECTS :
Gastrointestinal - nausea or vomiting

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rabbit

DOSE/DURATION :
18900 ug/kg

TOXIC EFFECTS :
Behavioral - muscle weakness Gastrointestinal - hypermotility, diarrhea Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
LDLo - Lowest published lethal dose

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - rabbit

DOSE/DURATION :
15 mg/kg

TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section

TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :
Intravenous

SPECIES OBSERVED :
Rodent - guinea pig

DOSE/DURATION :
25 mg/kg

TOXIC EFFECTS :
Vascular - BP elevation not characterized in autonomic section

TYPE OF TEST :
LD10 - Lethal Dose

ROUTE OF EXPOSURE :
Parenteral

SPECIES OBSERVED :
Rodent - hamster

DOSE/DURATION :
140 mg/kg

TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
2520 mg/kg/12W-I

TOXIC EFFECTS :
Endocrine - changes in spleen weight Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - changes in testicular weight

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1092 mg/kg/30D-I

TOXIC EFFECTS :
Endocrine - changes in thymus weight Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
6552 mg/kg/26W-I

TOXIC EFFECTS :
Endocrine - changes in thymus weight Liver - changes in liver weight Blood - changes in erythrocyte (RBC) count

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
700 mg/kg/40W-I

TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
1283 mg/kg/13W-C

TOXIC EFFECTS :
Behavioral - fluid intake Endocrine - changes in thymus weight Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
360 mg/kg/60D-I

TOXIC EFFECTS :
Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
780 mg/kg/30D-I

TOXIC EFFECTS :
Endocrine - changes in thymus weight Blood - normocytic anemia Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
2340 mg/kg/13W-I

TOXIC EFFECTS :
Liver - changes in liver weight Kidney, Ureter, Bladder - changes in bladder weight Blood - normocytic anemia

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
21 mg/kg/7D-I

TOXIC EFFECTS :
Blood - changes in bone marrow (not otherwise specified) Blood - changes in leukocyte (WBC) count Blood - changes in platelet count

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Rectal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
4920 mg/kg/90D-I

TOXIC EFFECTS :
Gastrointestinal - other changes Endocrine - other changes Nutritional and Gross Metabolic - weight loss or decreased weight gain

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Rectal

SPECIES OBSERVED :
Rodent - rat

DOSE/DURATION :
9540 mg/kg/26W-I

TOXIC EFFECTS :
Gastrointestinal - other changes Endocrine - other changes Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
300 mg/kg/60D-I

TOXIC EFFECTS :
Endocrine - changes in spleen weight Related to Chronic Data - death Related to Chronic Data - changes in testicular weight

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
455 mg/kg/13W-I

TOXIC EFFECTS :
Behavioral - food intake (animal) Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

SPECIES OBSERVED :
Mammal - dog

DOSE/DURATION :
175 mg/kg/5W-I

TOXIC EFFECTS :
Behavioral - convulsions or effect on seizure threshold Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

SPECIES OBSERVED :
Rodent - mouse

DOSE/DURATION :
1500 mg/kg/50W-I

TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Lungs, Thorax, or Respiration - tumors Blood - tumors

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
150 mg/kg

SEX/DURATION :
female 20-31 week(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - other neonatal measures or effects

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
240 mg/kg

SEX/DURATION :
female 11-14 week(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
35 mg/kg

SEX/DURATION :
female 7-13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
175 mg/kg

SEX/DURATION :
female 7-13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
15 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetal death Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
30 mg/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue) Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - gastrointestinal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
30 mg/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
20 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
20 mg/kg

SEX/DURATION :
female 14 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Subcutaneous

DOSE :
30 mg/kg

SEX/DURATION :
female 14 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
330 mg/kg

SEX/DURATION :
female 7-17 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
175 mg/kg

SEX/DURATION :
female 7-13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Oral

DOSE :
245 mg/kg

SEX/DURATION :
female 7-13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - litter size (e.g. # fetuses per litter; measured before birth) Reproductive - Effects on Embryo or Fetus - fetal death

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
50 mg/kg

SEX/DURATION :
female 13 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - cytological changes (including somatic cell genetic material)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
20 mg/kg

SEX/DURATION :
female 10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
20 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - other developmental abnormalities

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
30 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - abortion

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
10 mg/kg

SEX/DURATION :
female 10 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - eye/ear Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intraperitoneal

DOSE :
30 mg/kg

SEX/DURATION :
female 12 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Newborn - live birth index (measured after birth) Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intravenous

DOSE :
67 mg/kg

SEX/DURATION :
male 1 day(s) pre-mating

TOXIC EFFECTS :
Reproductive - Paternal Effects - spermatogenesis (incl. genetic material, sperm morphology, motility, and count)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intramuscular

DOSE :
24 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intramuscular

DOSE :
28 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - musculoskeletal system

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intramuscular

DOSE :
56 mg/kg

SEX/DURATION :
female 11 day(s) after conception

TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - homeostasis

TYPE OF TEST :
TDLo - Lowest published toxic dose

ROUTE OF EXPOSURE :
Intramuscular

DOSE :
20 mg/kg

SEX/DURATION :
female 9 day(s) after conception

TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)

TYPE OF TEST :
Specific locus test

TYPE OF TEST :
DNA inhibition

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
Unscheduled DNA synthesis

TYPE OF TEST :
DNA inhibition

TYPE OF TEST :
Mutation test systems - not otherwise specified

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Cytogenetic analysis

TYPE OF TEST :
Sperm Morphology

TYPE OF TEST :
Sperm Morphology

TYPE OF TEST :
Micronucleus test

TYPE OF TEST :
Cytogenetic analysis

MUTATION DATA

TYPE OF TEST :
DNA inhibition

TEST SYSTEM :
Mammal - species unspecified Cells - not otherwise specified

DOSE/DURATION :
100 umol/L

REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 120,139,1983 *** REVIEWS *** IARC Cancer Review:Animal Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,217,1981 IARC Cancer Review:Human Inadequate Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) V.1- 1972- Volume(issue)/page/year: 26,217,1981 IARC Cancer Review:Group 3 IMSUDL IARC Monographs, Supplement. (WHO Publications Centre USA, 49 Sheridan Ave., Albany, NY 12210) No.1- 1979- Volume(issue)/page/year: 7,210,1987 TOXICOLOGY REVIEW NEJMAG New England Journal of Medicine. (Massachusetts Medical Soc., 10 Shattuck St., Boston, MA 02115) V.198- 1928- Volume(issue)/page/year: 291,75,1974 TOXICOLOGY REVIEW MIMDAL Minnesota Medicine. (Minnesota Medical Assoc., 2221 University Ave., SE, Suite 400, Minneapolis, MN 55414) V.1- 1918- Volume(issue)/page/year: 57,19,1974 TOXICOLOGY REVIEW JAMAAP JAMA, Journal of the American Medical Association. (AMA, 535 N. Dearborn St., Chicago, IL 60610) V.1- 1883- Volume(issue)/page/year: 172,1765,1960 TOXICOLOGY REVIEW 32XPAD "Teratology," Berry, C.L., and D.E. Poswillo, eds., New York, Springer, 1975 Volume(issue)/page/year: -,49,1975 TOXICOLOGY REVIEW JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 144,429,1964 TOXICOLOGY REVIEW ARVPAX Annual Review of Pharmacology. (Palo Alto, CA) V.1-15, 1961-75. For publisher information, see ARPTDI. Volume(issue)/page/year: 5,447,1965 TOXICOLOGY REVIEW CRTXB2 CRC Critical Reviews in Toxicology. (CRC Press, Inc., 2000 Corporate Blvd., NW, Boca Raton, FL 33431) V.1- 1971- Volume(issue)/page/year: 2,159,1973 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X4035 No. of Facilities: 681 (estimated) No. of Industries: 2 No. of Occupations: 9 No. of Employees: 23501 (estimated) No. of Female Employees: 15547 (estimated)

Safety Information

Symbol	GHS06
Signal Word	Danger
Hazard Statements	H301-H412
Precautionary Statements	P273-P301 + P310
Hazard Codes	Xn:Harmful
Risk Phrases	R20/21/22
Safety Phrases	S36-S36/37
RIDADR	UN 2811 6.1/PG 3
WGK Germany	3
RTECS	YR0350000
Packaging Group	III
Hazard Class	6.1
HS Code	2933599090

Synthetic Route

Previous 1/27 Next

cytosine

71-30-7

~79%

Fluorouracil

51-21-8

Literature: Daikin Kogyo Co., Ltd.; Asahi Chemical Industry Co., Ltd. Patent: US4122251 A1, 1978 ;

Uracil

66-22-8

~92%

Fluorouracil

51-21-8

Literature: Yemul, S. S.; Kagan, H. B.; Setton, R. Tetrahedron Letters, 1980 , vol. 21, p. 277 - 280

Cytosine hydroc...

1784-08-3

~64%

Fluorouracil

51-21-8

Literature: Daikin Kogyo Co., Ltd.; Asahi Chemical Industry Co., Ltd. Patent: US4122251 A1, 1978 ;

Precursor & DownStream

Precursor 9	Previous 1/3 Next
CAS#:71-30-7 cytosine CAS#:66-22-8 Uracil CAS#:1784-08-3 Cytosine hydroc... CAS#:75500-02-6 2,4(1H,3H)-Pyri...
DownStream 10	Previous 1/3 Next
CAS#:105434-88-6 5-fluoro-1-(4-m... CAS#:105411-89-0 1-(4-butoxyphen... CAS#:111854-27-4 1,3-bis(ethenyl... CAS#:72975-39-4 1-vinyl-5-fluor...

Customs

HS Code	2933599090
Summary	2933599090. other compounds containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

2. Packaging of materials

For powders: normal is 25kgs/Drum or bag, or larger/smaller package as request.
For liquids: normal 25kgs/drum, 180-300kgs/bucket, or IBC, determined by the nature of the product.

Or smaller package 1kg/bottle, 10kgs/bottle as request.

3. Shipping & Delivery

By Express

Provide door to door service

Suitable for goods under 50kg

Delivery: 3-7 days

Cost: low cost

By Air

Provide airport to airport service

Suitable for goods over 50kg

Delivery: 3-14 days

Cost: high cost

By Sea

Provide seaport to seaport service

Suitable for goods over 100kg

Delivery: 2-45 days

Cost: low cost

4. Contact information

For more details, pls contact us freely.

Email address: Tina@fdachem.com

Mob: 86 13213167925

WhatsApp/Skype/Wechat/LINE: 86 13213167925

show less show more

Company Profile Introduction

Henan Fengda Chemical Co., Ltd. is located in the High-tech Development Zone of Henan Province. Specializing in the production and sales of various fine chemical products required for industrial production, including chemical raw materials, organic raw materials, petrochemicals, chemical reagents, solvents, catalysts, and additives, etc.